Telo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telo

What is Telo? Definition and Pharmacological Classification

Property Description
Active ingredient Cefditoren Pivoxil (Prodrug)
Form Film-coated tablets
Pharmacological class Third-generation Cephalosporin, beta-Lactam antibiotic
Common use Systemic bacterial infections
Origin Semisynthetic

Telo is a prescription-only medicine whose active component is Cefditoren Pivoxil, classified as a systemic beta-Lactam antibiotic. It is specifically identified as a third-generation cephalosporin, which positions it within the major category of antibacterial agents designed to target systemic infections. This classification, based on its structure and stability against many bacterial enzymes, confirms its role as a vital therapeutic option for controlling a broad range of bacterial pathogens.

The active ingredient, Cefditoren Pivoxil, is a single-component, semisynthetic compound that functions as an inactive prodrug. This prodrug is specifically designed to be efficiently absorbed after oral administration and immediately converted by the body's esterases into the active antibiotic, Cefditoren. This specialized oral form offers a practical distinguishing feature for the management of infections compared to some injectable cephalosporins.

The general purpose of Telo is to provide bactericidal action for the elimination of systemic bacterial infections caused by susceptible organisms. Its mechanism involves the inhibition of bacterial cell wall synthesis, a critical process that ensures the medicine actively kills the targeted bacterial cells, rather than merely preventing their replication. This foundational action is essential for the resolution of underlying infectious diseases.

What side effects are possible with Telo?

Possible Side Effects and Safety Information

The safety profile of Telo (Cefditoren Pivoxil) is officially classified by regulatory documents, which categorize known effects by frequency and the body system affected. These classifications ensure transparency regarding the documented risks associated with its use.


Documented Adverse Reactions

The most Common side effects reported in regulatory trials include diarrhea, nausea, headache, and vaginal moniliasis. Uncommon effects may involve abdominal pain and dyspepsia. Side effects are typically grouped by the System-Organ Class they affect, such as Gastrointestinal Disorders (the most frequent category), Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.


Serious Safety Concerns

The official label documents several Serious Adverse Reactions, which are often rare but clinically significant. These include severe, acute hypersensitivity events like Anaphylaxis and serious skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The medication also carries a warning regarding the potential for Pseudomembranous Colitis (or Clostridium difficile-associated diarrhea), which may occur during or after therapy.


Population and Formulation Safety Constraints

The official labeling notes specific safety constraints. Telo is contraindicated in individuals with a documented hypersensitivity to Cefditoren Pivoxil, other cephalosporin antibiotics, or penicillins. Due to the presence of sodium caseinate, it is also contraindicated in individuals with a severe milk protein allergy (distinct from lactose intolerance). Additionally, due to the drug’s pivalate component, it is contraindicated in individuals with Carnitine Deficiency. Regulatory observations indicate increased systemic exposure to the active component in older adults and patients with moderate to severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation states that information regarding Telo (Cefditoren Pivoxil) overdosage in humans is limited. The documented potential effects of overdosage are therefore based on the known profile of other beta-Lactam antibiotics, which is the drug's pharmacological class.

Documented Overdose Manifestations

Potential clinical signs of overdosage, projected from the antibiotic class, include gastrointestinal effects such as nausea, vomiting, diarrhea, and epigastric distress. A potential severe outcome associated with beta-Lactam antibiotic overdosage is the occurrence of convulsions (seizures).

Emergency Actions and Required Care

Management of a suspected overdose is focused on symptomatic treatment and the institution of supportive measures as required by regulatory guidance. There is no specific pharmaceutical antidote listed in the prescribing information.

Government health guidance mandates immediate action in severe scenarios. If an individual has collapsed, has had a seizure, is experiencing trouble breathing, or cannot be awakened, emergency services must be called immediately. For all suspected overdosage situations, the poison control helpline should be contacted for advice.

Procedural and Population Notes

A documented procedural measure is that hemodialysis may be utilized to aid in the removal of Cefditoren from the body. This drug removal procedure is specifically noted as being particularly relevant and effective if renal function is compromised.

Therapeutic Uses of Telo

What Telo Treats: Main Uses and Benefits

Telo (Cefditoren Pivoxil) is primarily used to address bacterial infections across several key organ systems, with the goal of targeting the bacterial source and contributing to improved comfort during periods of heightened symptoms these infections manifest. The therapeutic benefit is centered on managing the burden of symptoms that interfere with daily function. This medication is considered relevant for managing acute bacterial illnesses across key domains, including the respiratory tract, the oropharynx, and the skin.

The medicine is commonly used across conditions presenting with acute episodes, such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, bacterial pharyngitis/tonsillitis, acute maxillary sinusitis, and uncomplicated skin and skin structure infections. It helps address symptom clusters that may become intense or disruptive, including severe sore throat, persistent cough, pain, swelling, and redness.

“Telo is applied in clinical settings that involve acute or unstable symptom patterns, and may provide symptomatic relief that helps patients cope more steadily with difficult episodes.”


Quick Fact: Relief for Acute Infections
May support the patient during difficult episodes by contributing to easing distress associated with acute respiratory, skin, and oropharyngeal infections.

Telo is applied in scenarios where additional management of discomfort is required, and the medication may assist with managing the infection while contributing to easing the overall symptom load on the affected organs.

Eligibility and Restrictions for Use

Who Can and Cannot Use Telo (telotristat ethyl)

Official regulatory documentation establishes specific eligibility criteria and restrictions for the use of telotristat ethyl in adults.

Populations for Whom Use is Restricted or Prohibited

Classification Population / Condition Restriction Basis (Official Statement)
Contraindicated Patients with a history of hypersensitivity to telotristat or any of its components. Formal exclusion from use (e.g., risk of angioedema, rash).
Use Not Recommended Patients with moderate or severe hepatic impairment (Child-Pugh B or C). Safety not established in these specific patient populations.
Use Not Recommended Patients with end-stage renal disease requiring dialysis (eGFR < 15 mL/min). Safety and efficacy have not been established.
Requires Contraception Females of reproductive potential. Potential risk of fetal harm; must use effective contraception during treatment.
Mandatory Discontinuation Patients who develop severe constipation or severe, persistent, or worsening abdominal pain. Use must be stopped immediately upon the development of these severe gastrointestinal symptoms.

Age-Related Eligibility

Telotristat ethyl is indicated for use in adults (18 years of age and older). Safety and effectiveness in pediatric patients have not been established. The drug can be used in geriatric patients (ge 65 years) with no observed differences in safety or effectiveness relative to younger adults.

What should I know about interactions with other medicines?

Telmisartan (Telo) is an angiotensin II receptor blocker, and its interactions primarily involve other medicines that affect the body's fluid balance, blood pressure, or potassium levels.

Contraindicated Combination

The dual blockade of the Renin-Angiotensin System (RAS) is restricted. Telmisartan must not be used concomitantly with aliskiren in individuals with diabetes or moderate-to-severe kidney impairment, as this significantly increases the risk of hypotension, hyperkalemia (high potassium), and acute kidney failure.

Major Interaction Categories

Interacting Product Category Potential Risk Mechanism/Note
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen) Increased risk of kidney problems; reduced effectiveness of Telo. NSAIDs can impair kidney function and diminish the antihypertensive effect. The risk is higher in older patients or those with volume depletion.
Other RAS Inhibitors (e.g., ACE inhibitors, other ARBs) Increased risk of severe hypotension, hyperkalemia, and kidney changes. This combination is generally avoided due to the dual blockade of the RAS.
Potassium Supplements or Spironolactone Risk of hyperkalemia. Telo itself can raise potassium; adding potassium-elevating agents increases the risk of dangerously high potassium levels.
Digoxin Increased Digoxin concentration in the bloodstream. Telo can increase the levels of Digoxin, necessitating close therapeutic drug monitoring when co-administered.

Individuals should inform their healthcare provider of all medicines, supplements, and potassium-containing salt substitutes they are taking to manage potential drug interactions.

Mechanism of Action

How Telo Works


The action of Cefditoren (Telo) is determined by its ability to engage and irreversibly inhibit essential bacterial enzymes, which rapidly translates into the destruction of the pathogen's protective structure. The following mechanisms govern its physiological effect:

Irreversible Blockade of Bacterial Cell Wall Assembly

This core mechanism involves the drug acting as a covalent inhibitor against specific Penicillin-Binding Proteins (PBPs), which are bacterial enzymes required for building the cell wall. By disabling these enzymes, Cefditoren halts the final stages of peptidoglycan cross-linking. This targeted molecular interference leads directly to the loss of structural integrity, a cellular event that results in the rapid, bactericidal (cell-killing) action that drives the elimination of the bacterial population.


Mechanism Constraints and Resistance Pathways

The physiological success of Cefditoren is functionally constrained by bacterial defense mechanisms, including Enzymatic Inactivation and Target Modification. The beta-Lactam ring can be hydrolyzed by bacterial beta-Lactamase enzymes, or the target PBPs can be genetically altered to exhibit reduced affinity for Cefditoren. Where these resistance pathways dominate, the primary inhibitory mechanism fails to engage, allowing the bacterial proliferation to continue cellular proliferation.

Dosage and Administration Information

How to Use Telotristat Ethyl (Xermelo)

Telotristat ethyl is an oral medicine administered as a 250 mg film-coated tablet. The instructions for use are as outlined below, with all doses taken with food.

Administration Guidelines

The recommended dosage for adult patients is 250 mg three times daily (tid), taken by mouth. No relevant use is established in the pediatric population.

Administration Component Instruction
Route and Dosing Oral, 250 mg film-coated tablet three times daily.
Timing with Meals Must be taken with food.
Missed Dose If a dose is missed, the patient should skip that dose and take the next dose at the regular scheduled time. Do not take two doses to make up for a missed dose.
Concomitant Octreotide If short-acting octreotide is used, it must be administered at least 30 minutes after the dose of Telotristat ethyl.

Dose Adjustments and Restrictions

The required dose may be adjusted based on the patient's liver function, according to tolerability:

  • Mild Hepatic Impairment (Child-Pugh A): The dose may need to be reduced to 250 mg twice daily.
  • Moderate Hepatic Impairment (Child-Pugh B): The dose may need to be reduced to 250 mg once daily.

Use is not recommended for patients with severe hepatic impairment (Child-Pugh C) or end-stage renal disease (eGFR < 15 mL/min) requiring dialysis.

Therapy Duration

Clinical response is generally achieved within 12 weeks of starting treatment. It is recommended to reassess the benefit of continuing therapy if no response is observed within this time period. Discontinuation of the medicine is required if severe constipation or suspected liver injury develops.

Recent Clinical Evidence

Research evidence / Overview of studies for Telo

Evidence for Acute Exacerbations of Chronic Bronchitis (AECB) and Pneumonia (CAP)

Research into Telo's use for lower respiratory infections, such as Acute Exacerbations of Chronic Bronchitis (AECB) and Community-Acquired Pneumonia (CAP), has relied primarily on clinical trials, such as Randomized Controlled Trials (RCTs) and pooled analyses. These short-term studies were designed to compare Telo against other established oral antibiotics. Researchers focused on measuring specific outcomes, including clinical response rates (used in research exploring how symptoms change over time) and microbiological eradication rates against common bacterial causes. The studies included adults and adolescents experiencing these acute episodes.

The findings describe patterns observed in the studies where reported measurements of clinical success were often compared to the established success rates achieved by active comparator drugs. Trial summaries frequently documented that the reported outcomes were within the predefined study criteria when compared to the active control agents. Data for severe CAP or long-term outcomes for AECB remain limited.


Evidence for Pharyngitis, Tonsillitis, and Sinusitis

Telo was studied for acute infections of the upper respiratory tract and oropharynx. Research explored pharyngitis/tonsillitis and acute maxillary sinusitis using multicenter comparative clinical trials. Researchers monitored outcomes related to physical discomfort and clinical cure/success, along with microbiological eradication (specifically of Streptococcus pyogenes in pharyngitis trials). The studies included both adults and children/adolescents.

Studies report how symptoms evolved in the observed populations, noting measurements of bacterial eradication rates. The clinical and microbiological outcomes were within the predefined study criteria compared to the established treatments. There is limited information for long-term outcomes regarding recurrence or the impact of varying regional bacterial resistance patterns.


Evidence in Special Populations and Uncertainties

For conditions like pharyngitis and acute rhinosinusitis, dedicated pediatric studies included children and adolescents and described outcomes related to age-specific response patterns. However, data for certain groups remain insufficient, including evidence for older adults with multiple chronic conditions (comorbidities) or studies examining the use of Telo in pregnant or breastfeeding women. The results apply only to the populations studied.

Most pivotal trials were studied for non-inferiority compared to established treatments, and comparative evidence is lacking regarding superiority. The follow-up durations were limited in most pivotal studies, meaning long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Telo (FAQ)


Q: Can Telo be taken by people who are generally healthy?

Telo is a prescription antibiotic indicated by regulatory documents for treating specific bacterial infections. It is not generally described for use by individuals who do not have a susceptible bacterial infection that requires treatment.


Q: How does Telo relate to other treatments for the same condition?

According to official product information, Telo is classified as a third-generation cephalosporin antibiotic. Clinical studies often compare its reported effectiveness against other established oral antibiotics (known as active controls) used for the same types of infections.


Q: How often do people typically experience the side effects listed for Telo?

Regulatory trial data provides an indication of how often certain effects may occur. For adult and adolescent patients taking Telo, the most common side effects like diarrhea are reported to occur in 11%–15% of patients, and nausea is reported in 4%–6% of patients.


Q: Is it normal to feel a specific sensation (like mild dizziness or nausea) when first starting Telo?

Nausea and headache are listed in official documents as common adverse reactions documented during clinical trials. Dizziness is also a documented reaction, but it is reported less commonly, occurring in less than 1% of patients.


Q: Does Telo affect my ability to concentrate or drive?

Official documents report side effects like dizziness and headache. The presence of these reported side effects is the reason general drug safety information recommends individuals should exercise caution when driving or operating complex machinery until they understand the medication's effect.


Q: What are the results of the key research studies on Telo?

The main clinical trials reported specific outcomes, such as rates of clinical and microbiological success. These results were generally found to be within the predefined study criteria when compared to the outcomes achieved by control antibiotics.


Q: What is the long-term research evidence on Telo (after several years of use)?

Official regulatory documents indicate that the follow-up durations in most of the main clinical studies were limited. This means that the long-term effects of this medication, after several years of use, are not fully established.


Q: Are there specific symptoms that signal a rare but serious side effect of Telo?

Yes, regulatory documents describe several serious adverse reactions. Symptoms that are reported to require immediate medical attention include watery or bloody stools, severe stomach cramps, fever, hives, rash, or any difficulty breathing or swelling of the face.


Q: Will taking Telo affect my fertility or family planning?

Official information notes that females who can become pregnant are required to use effective contraception while on this treatment due to the potential risk of harm to an unborn fetus. Data on the impact of Telo on fertility are not established in the official documents.


Q: Does Telo interfere with common health supplements like vitamins or minerals?

Official drug interaction information specifies an interaction with certain antacids (stomach acid reducers) that contain high amounts of magnesium or aluminum. These can significantly reduce the absorption and effectiveness of Telo.


Q: Do other medicines make Telo less effective?

Yes, official drug interaction data indicates that certain antacids and medicines used to reduce stomach acid can make Telo less effective. This occurs because these products can significantly decrease the amount of the antibiotic absorbed into the body.


Q: Is Telo safe to use for individuals with pre-existing heart conditions?

Official information does not list common cardiovascular effects. The decision regarding the use of Telo in individuals with pre-existing heart conditions is a clinical consideration managed by a healthcare provider based on the known safety profile and the individual’s medical history.


Q: What is the official patient information leaflet for Telo called?

The official document containing patient information is typically referred to as the Patient Information Leaflet (PIL) in European regulatory sources or the Medication Guide in the United States.


Q: Can Telo be taken during pregnancy, according to official guidelines?

Telo is assigned an FDA Pregnancy Category B. Official documents state that its use during pregnancy is considered appropriate only when a healthcare provider determines that the potential benefit to the mother justifies any potential risk to the developing fetus.


Q: Can Telo cause unexpected weight changes?

Official regulatory documents list appetite changes (anorexia) as a documented adverse reaction that occurs rarely. Significant or unexpected changes in body weight are not listed as a common or serious adverse reaction.


Q: How is the safety profile of Telo described in regulatory documents?

Regulatory documents indicate that the majority of documented adverse events are reported as mild to moderate in severity, consistent with its safety profile, which helps healthcare providers weigh the benefits and risks.


Q: Can Telo be taken by people who are lactose intolerant or have other common allergies?

Telo is strictly contraindicated only for individuals with a known severe milk protein allergy due to one of its components. Official labeling notes that this is distinct from simple lactose intolerance, which is not listed as a contraindication.


Q: Are there warnings about taking Telo with alcohol?

The official drug interaction sections do not list a major warning with alcohol. While there is no official warning, general safety principles for drug use often recommend avoiding or limiting alcohol consumption while taking antibiotics.


Q: Does Telo interact with common over-the-counter pain relievers or cold medicines?

Official documents note an interaction with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, which may increase the risk of kidney problems. Patients should consult a healthcare provider regarding all over-the-counter medicines, including cold remedies.


Q: What is the time frame for Telo to start having its intended effect?

After taking the medicine, the inactive form is efficiently converted into the active antibiotic component. Clinically relevant concentrations of the active component are generally achieved in the affected body tissues within a few hours of the first dose.


Q: How long does a person generally need to take Telo?

Official dosage information specifies a length of treatment that depends on the type of infection being treated. The duration is defined in official labeling, with common examples ranging from 5 to 10 days for specific respiratory infections.


Q: What patient groups were included in the main clinical trials for Telo?

The main clinical trials included both adult and adolescent patients for respiratory and skin infections. Dedicated pediatric studies were also conducted, which included children and adolescents for upper respiratory infections.

How should Telo be stored and disposed of?

How to Store and Dispose of Telo?

Telo (Cefditoren Pivoxil) must be stored at Controlled Room Temperature, typically 25 C (77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medication must be protected from light and moisture and should be kept from freezing.

It is required that the tablets be stored in a tight, light-resistant container and that the container remains tightly closed when not in use. As a mandatory safety measure, Telo must be stored out of the reach of children.

For disposal, unused, expired, or no-longer-needed medication must be handled according to specific instructions from a healthcare professional and in accordance with local regulations. Do not release the product into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telo found in:

A-Z Index: